Vanguard Global Advisers
NVNO

Vanguard Global Advisers’s enVVeno Medical NVNO Stock Holding History

Vanguard Global Advisers’s Portfolio NVNO Stock Details NVNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$825 Hold
77
– – ﹤0.01% 3623
2026
Q1 		$780 Buy
+77
New +$843 ﹤0.01% 3644

Other funds holding NVNO

KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Vanguard Global Advisers's NVNO Position: Q2 2026 in Review

Vanguard Global Advisers held its enVVeno Medical (NVNO) position steady in Q2 2026 at 77 shares worth $825. The position accounts for ﹤0.01% of the portfolio, ranked #3623.

Vanguard Global Advisers first reported a position in NVNO in Q1 2026 and has held it in 2 quarters since. 17 funds tracked by Wall St. Rank hold NVNO as of Q2 2026.

  • Vanguard Global Advisers held 77 shares of enVVeno Medical worth $825 as of Q2 2026.
  • Vanguard Global Advisers left its enVVeno Medical share count unchanged in Q2 2026.
  • enVVeno Medical made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3623 holding.
  • Vanguard Global Advisers first reported a position in enVVeno Medical in Q1 2026 and has held it in 2 quarters since.
  • 17 funds tracked by Wall St. Rank held enVVeno Medical as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.